$Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study$

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study

Abstract The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at lea...

Full description

Bibliographic Details
Main Authors:	Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Anita D’Souza, Aniko Szabo, Carolina Schinke, Rajshekhar Chakraborty
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-03-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-024-01003-z

Similar Items

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
by: Rajshekhar Chakraborty, et al.
Published: (2023-11-01)

Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report
by: Anannya Patwari, et al.
Published: (2020-08-01)

Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States
by: Samer Al Hadidi, et al.
Published: (2022-07-01)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
by: Faris Jamal Abu Za'nouneh, et al.
Published: (2023-05-01)

Use of daratumumab in high risk multiple myeloma: A meta‐analysis
by: Vikram Premkumar, et al.
Published: (2020-07-01)

3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns
by: Carolina Schinke, et al.
Published: (2019-03-01)

EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
by: Wen Ling, et al.
Published: (2023-09-01)

Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma
by: George Mellgard, et al.
Published: (2024-03-01)

Teclistamab: Mechanism of action, clinical, and translational science
by: Yue Guo, et al.
Published: (2024-01-01)

Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant
by: Pankaj Mathur, et al.
Published: (2017-09-01)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
by: Rajshekhar Chakraborty, et al.
Published: (2023-08-01)

Impressive extramedullary plasmacytoma response in refractory multiple myeloma treated with teclistamab
by: Intissar Ben Salah, et al.
Published: (2024-02-01)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
by: Lakshmi Yarlagadda, et al.
Published: (2021-08-01)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
by: Samrat Roy Choudhury, et al.
Published: (2020-08-01)

First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
by: Nelson Leung, et al.
Published: (2023-11-01)

Editorial: Advances in the understanding of pathogenesis, diagnosis, and therapy of light chain amyloidosis
by: Divaya Bhutani, et al.
Published: (2023-02-01)

Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
by: Wancheng Guo, et al.
Published: (2024-02-01)

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience
by: Sara A. Scott, et al.
Published: (2023-12-01)

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
by: NWCJV Donk, et al.
Published: (2023-10-01)

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody
by: Pan D, et al.
Published: (2023-07-01)

Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
by: Kristin Larsen, et al.
Published: (2022-03-01)

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
by: Carlyn Tan, et al.
Published: (2023-08-01)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
by: Manisha Bhutani, et al.
Published: (2023-08-01)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
by: Leo Rasche, et al.
Published: (2022-08-01)

A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
by: Wancheng Guo, et al.
Published: (2024-03-01)

A gene signature can predict risk of MGUS progressing to multiple myeloma
by: Fumou Sun, et al.
Published: (2023-06-01)

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS
by: Kristine Frerichs, et al.
Published: (2023-08-01)

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
by: Amrita Krishnan, et al.
Published: (2023-04-01)

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
by: Fumou Sun, et al.
Published: (2024-01-01)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
by: Ross Firestone, et al.
Published: (2023-08-01)

PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: A. Krishnan, et al.
Published: (2022-06-01)

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
by: Fritz Offner, et al.
Published: (2023-08-01)

Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
by: Noa Biran, et al.
Published: (2021-08-01)

P940: AN OUTPATIENT MODEL FOR TECLISTAMAB STEP-UP DOSING ADMINISTRATION – INITIAL EXPERIENCES AT FOX CHASE CANCER CENTER BMT PROGRAM.
by: Asya Nina Varshavsky-Yanovsky, et al.
Published: (2023-08-01)

Differences across cyclophilin A orthologs contribute to the host range restriction of hepatitis C virus
by: Jenna M Gaska, et al.
Published: (2019-05-01)

Gender disparities in multiple myeloma publications
by: Aala Dweik, et al.
Published: (2022-08-01)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
by: Dongzheng Gai, et al.
Published: (2022-09-01)

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS
by: C. Touzeau, et al.
Published: (2022-06-01)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
by: L. Rosinol, et al.
Published: (2022-06-01)

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
by: M. V. Mateos, et al.
Published: (2022-06-01)